Clinical Trial Update: Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 1]

View source ↗

Summary

This Phase 1 dose-escalation trial of BCX10013 in Paroxysmal nocturnal hemoglobinuria has completed its dose-escalation portion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• BCX10013

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Status: COMPLETED